NCT03925324终止2 期
A Randomized, Double-Blind, Placebo-Controlled Phase IIa Study of the Safety and Efficacy of Intravenous Delivery of Allogeneic Mesenchymal Stem Cells in Cardiomyopathy Patients and Implanted Left Ventricular Assist Device
Medstar Health Research Institute2 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2019年5月3日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 4
- 试验地点
- 2
- 主要终点
- Uncontrolled Systemic Infection
研究概览
简要总结
A study to assess the safety and preliminary efficacy of serial intravenous dose of Allogeneic Mesenchymal Bone Marrow Cells in subjects with heart failure and implanted left ventricular assist devices.
详细描述
A double-blind, placebo-controlled, single-center, randomized study to assess the safety and preliminary efficacy of a three serial intravenous doses of allogeneic mesenchymal bone marrow cells to subjects with heart failure and implanted left ventricular assist devices.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years.
- •Advanced Heart Failure
- •Advanced HF defined as HF requiring LVAD implantation and deemed stable on his/her LVAD.
- •On stable medical therapy (per the discretion of the treating physician) including beta-blockers, ACE-inhibitors, angiotensin receptors blockers, angiotensin receptor neprilysin inhibitor, mineralocorticoid receptor antagonists, isosorbide, hydralazine, and mineralocorticoid receptor antagonists) and optimized pump speed for at least a month prior to randomization.
- •HS-CRP level≥2 mg/l.
- •NYHA class II-III symptoms.
- •Ability to understand and provide signed informed consent.
- •Reasonable expectation that patient will receive standard post-treatment care and attend all scheduled safety follow-up visits
排除标准
- •Women of childbearing potential. Postmenopausal women or women with permanent contraception method (defined as total hysterectomy) will not be excluded.
- •History of debilitating stroke (modified Rankin Score > 3) within 3 months.
- •The likelihood of requirement of cardiac surgery during the study period.
- •Presence of clinically significant, uncorrected left sided valvular heart disease, active acute myocarditis, or uncontrolled hypertension defined as Persistently elevated mean arterial blood pressure (>100 mmHg). Echocardiography within 12 months of screening. Patients can be re-evaluated, at the discretion of the investigator.
- •QTc >550 ms (in the absence of bundle branch block, interventricular conduction delay or ventricular pacing). Electrocardiogram (ECG) within 60 days.
- •History of cardiac arrest within 3 months.
- •Hypertrophic or infiltrative cardiomyopathy.
- •Considered or listed for organ transplantation or history of organ transplantation
- •Illness other than HF with life expectancy less than 12 months.
- •Enrolled in an interventional trial or received an experimental drug or device within 30 days of randomization.
- •Left ventricular assist device implantation >2 years prior to enrollment.
- •Biventricular assist device (Bi-VAD) support.
- •Severe COPD defined by FEV1<1L, FEV1/FVC<70% within 12 months if known history of COPD, otherwise FEV1<1L, FEV1/FVC<70% within 24 months
- •Uncontrolled seizure disorder.
- •Clinically significant hematologic, hepatic, or renal impairment as determined by screening clinical laboratory tests within the last 30 days:
- •Liver disease = ALT or AST > 3x normal, alkaline phosphatase or bilirubin >2x normal Renal disease = on long term dialysis Hematologic = Unexplained persistent leukocytosis (WBC >11 K/UL) or hemoglobin < 8.5 gm/dl
- •Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the investigator or sponsor may affect compliance with the study protocol or pose a safety risk to the subject.
- •Inability to comply with the conditions of the protocol.
- •Acute coronary syndrome within 4 weeks (clinical diagnosis, confirmed by electrocardiographic abnormalities and elevation of troponin-I).
- •Malignancy within the previous five years, except adequately treated basal cell carcinoma, provided that it is neither infiltrating nor sclerosing, and carcinoma in situ of the cervix.
- •Active uncontrolled systemic infection. Positive blood or deep tissue cultures or clinical or imaging evidence of systemic infection despite complete course of effective antimicrobial therapy as determined by infectious diseases. Localized (non-systemic) infection is not an exclusion criterion. Patients can be re-evaluated, at the discretion of the investigator.
- •Early postpartum cardiomyopathy (within six months of diagnosis).
- •Presence of inherited or acquired immune deficiency or human immunodeficiency virus infection (HIV). Negative HIV test within the preceding 12 months is required.
- •Systemic corticosteroids, immunosuppressive drug therapy (cyclophosphamide, methotrexate, cyclosporine, tacrolimus, azathioprine, mycophenolate, sirolimus, etc.), and DNA depleting or cytotoxic drugs taken within four weeks prior to study treatment.
- •Known Porphyria.
- •Allergy to sodium citrate or any caine type of local anesthetic.
- •Patient enrolled in hospice care.
结局指标
主要结局
Uncontrolled Systemic Infection
时间窗: up to 12 months post enrollment
Number of admission for uncontrolled systemic infection
Temperature
时间窗: up to 12 months post enrollment
Temperature
All-cause Mortality
时间窗: up to 12 months post enrollment
Rate of Death
次要结局
- 6 Minute Walk Distance Changes(Baseline and day 90 post initial infusion)
- Change in RV Systolic Function(Baseline and day 90 post initial infusion)
- Hospitalizations Due to Right Heart Failure(day 90)
- Gout Flares(Day 90)
- Change in the Following Cardiac Biomarker(Baseline and day 90 post initial infusion)
- NK Cell Depletion(Baseline to day 90)
研究者
研究点 (2)
Loading locations...
相似试验
撤回
1 期
Ex Vivo Cultured Adult Allogenic MSCs in Ischemic Cerebral StrokeStrokeNCT01091701Stempeutics Research Pvt Ltd
已完成
1 期
Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19Covid19NCT04716998BonusBio Group Ltd50
终止
2 期
Phase IIa Clinical Study of N-Rephasin® SAL200Staphylococcus Aureus BacteremiaAnti-Bacterial AgentsNCT03089697Intron Biotechnology, Inc.25
Unknown
1 期
A Pilot Study of FFP104 in Subjects With Crohn's DiseaseCrohn's DiseaseNCT02465944Fast Forward Pharmaceuticals24
已完成
1 期
Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple SclerosisMultiple SclerosisNCT01745783Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud26